Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cidofovir
Drug ID BADD_D00463
Description Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Indications and Usage For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)
Marketing Status approved
ATC Code J05AB12
DrugBank ID DB00369
KEGG ID D00273
MeSH ID D000077404
PubChem ID 60613
TTD Drug ID D04AAW
NDC Product Code 48954-728
UNII JIL713Q00N
Synonyms Cidofovir | HPMPC | GS 504 | GS-504 | GS504 | Cidofovir, Sodium Salt | Cidofovir Sodium | Cidofovir, (R)-isomer | Cidofovir Anhydrous | 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine | Vistide | Cidofovir, (+-)-isomer
Chemical Information
Molecular Formula C8H14N3O6P
CAS Registry Number 113852-37-2
SMILES C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flatulence07.01.04.002--
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Furuncle23.11.02.009; 11.02.05.008--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gastritis07.08.02.001--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Gingival pain07.09.13.010--
Gingivitis07.09.10.002; 11.01.04.013--
Glycosuria20.02.01.005--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemolytic anaemia01.06.03.002--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hemiplegia17.01.04.002--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatosplenomegaly09.01.05.002; 01.09.03.001--Not Available
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
Hiccups22.12.01.001; 07.01.06.009--
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hyperaesthesia17.02.06.004; 23.03.03.080--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene